close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.42 +0.92 (+0.78%)
Streaming Delayed Price Updated: 2:53 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
Via Stocktwits
CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week High
CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segment growth. 
Via Benzinga
A Glimpse of Gilead Sciences's Earnings Potential
 
Via Benzinga
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
Via Stocktwits
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More
Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 
Via Benzinga
3 Value Stocks We Approach with Caution
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
From Gilead Sciences, Inc.
Via Business Wire
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
Which S&P500 stocks are moving on Friday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes. 
Via Benzinga
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Via Get News
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade. 
Via Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
3 S&P 500 Stocks We Approach with Caution
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Intellectual Property Stocks
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
 
Via Benzinga
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today